Group 1 - The company held its fifth supervisory board meeting, where the use of idle raised funds was discussed and approved [1][2] - The supervisory board agreed to temporarily use up to RMB 110 million of idle raised funds to supplement working capital, enhancing operational efficiency and reducing financial costs [1][2] - The decision to change the use of part of the raised funds aligns with the company's actual business needs and complies with relevant regulations [2][3] Group 2 - The supervisory board approved the addition of expected daily related transactions for 2025, which are deemed necessary for the company's operations and business expansion [3] - All supervisory board members voted in favor of the proposals, with unanimous support reflected in the voting results [2][3]

Core Viewpoint - The company, Shandong Heda Group Co., Ltd., is changing part of the fundraising purpose from the issuance of convertible bonds to permanently supplement working capital, which is deemed necessary for its operational needs and will not adversely affect other investment projects [1][5][9]. Fundraising Overview - The company was approved to issue 6 million convertible bonds with a total fundraising amount of 600 million RMB, netting approximately 592.75 million RMB after deducting issuance costs [1][2]. - As of June 30, 2025, the company has utilized approximately 457.47 million RMB of the raised funds, leaving a balance of about 135.76 million RMB [2][4]. Fund Usage Details - The remaining funds include 120 million RMB that was temporarily used to supplement working capital and has since been returned [2][4]. - The company plans to terminate the investment project for "Hershey's annual production of 15 billion plant capsules and intelligent three-dimensional warehouse upgrade project," which was initially planned for an investment of 181.68 million RMB [5][6]. Reasons for Fund Usage Change - The decision to halt the aforementioned project is influenced by changes in the international situation and market environment, which have affected the project's feasibility [5][6]. - The remaining funds will be used for daily operations and business development, enhancing the efficiency of fund usage and alleviating financial pressure [5][8]. Impact of Fund Usage Change - The change in fund usage is considered a prudent adjustment that aligns with the company's operational needs and will not negatively impact other investment projects [5][8]. - The company aims to optimize resource allocation and reduce financial costs, thereby improving operational efficiency and safeguarding the interests of the company and its investors [8][9]. Approval Process - The board of directors and the supervisory board have approved the change in fund usage, which will be submitted for further approval at the shareholders' meeting and the bondholders' meeting [8][9].

Group 1 - The company held its 15th meeting of the 9th Supervisory Board on July 4, 2025, with all three supervisors present, and the meeting was convened in accordance with relevant laws and regulations [1][2]. - The Supervisory Board approved the decision to change part of the raised funds for permanent working capital, which is seen as a prudent decision to enhance the efficiency of fund utilization without harming the interests of the company and its shareholders [1][2]. - The proposal to increase daily related party transactions for the year 2025 was also approved, with the board stating that the pricing is based on fair and reasonable policies, referencing market prices, and will not affect the company's independence or harm the interests of small and medium investors [2]. Group 2 - The resolutions made by the Supervisory Board are subject to approval at the company's shareholders' meeting [2]. - The meeting's resolutions and decisions will be documented and made available for review [2].

Summary of Key Points Core Viewpoint The company, Opcon Vision Technology Co., Ltd., is changing part of its fundraising purpose to acquire a 75% stake in Suqian Shangyue Qicheng Hospital Management Co., Ltd. This strategic move aims to enhance operational efficiency and align with the company's long-term development goals. Group 1: Fundraising and Financial Overview - The actual amount raised from the stock issuance was RMB 149,406.89 million after deducting issuance costs, with funds received in June 2022 [2][3]. - As of December 31, 2024, the company has utilized RMB 39,677.38 million of the raised funds, with a remaining balance of RMB 12,726.07 million after accounting for interest and investment income [3][4]. - The company plans to redirect RMB 23,373.00 million from the "Community Optical Service Terminal Construction Project" to fund the acquisition of Shangyue Qicheng [4][5]. Group 2: Acquisition Details - The total investment for acquiring a 75% stake in Shangyue Qicheng is RMB 33,390.00 million, with RMB 23,373.00 million sourced from the raised funds and RMB 10,017.00 million from the company's own funds [5][9]. - The acquisition aligns with the company's dual-driven development strategy of "full optical products + all-age optical services," enhancing its market presence in Yunnan Province [7][8]. - Shangyue Qicheng has established a comprehensive operational system and possesses strong brand recognition and profitability potential in the region [7][12]. Group 3: Financial Performance and Projections - Shangyue Qicheng's audited financial data shows total assets of RMB 11,073.59 million and net assets of RMB 6,151.34 million as of the latest report [14]. - The company has committed to achieving specific net profit targets from 2025 to 2029, with a minimum of RMB 3,900 million in 2025 [24]. - Future revenue growth is projected based on the expansion of service offerings and market penetration strategies, with a focus on medical services and optical products [21][22].

Summary of Key Points Core Viewpoint The company, Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd., is undergoing changes in the use of raised funds, including new investment projects, adjustments in investment amounts, and delays in project timelines, to enhance operational efficiency and align with market opportunities. Group 1: Fundraising Overview - The company raised a total of RMB 2,277,875,164.30 from a non-public stock issuance, with a net amount of RMB 2,274,960,656.06 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, regulated by a tripartite agreement among the company, the sponsor, and the bank [2] Group 2: Fund Usage Status - As of June 30, 2025, the company has allocated funds to various projects, including the expansion of its life sciences platform and the construction of a biopharmaceutical R&D base [3][4] - The total investment for the projects is RMB 228,070.62 million, with cumulative investments of RMB 163,909.18 million [4] Group 3: Changes in Fund Usage - The company has proposed to change the use of funds for the "Taixing Project" and redirect remaining funds to new projects, including a chemical macromolecule project and a high-end formulation project [5][6] - The investment amount for the Taixing Project will be reduced by RMB 400 million, with the remaining funds allocated to new projects [6][11] Group 4: New Investment Projects - A new project, the "Chemical Macromolecule Integration Project," will receive RMB 47,367.72 million from the remaining funds, with a total investment of RMB 50,800.00 million [11][12] - The project aims to enhance the company's capacity in the CDMO field and is expected to take 48 months to complete [12][14] Group 5: Financial Performance - The company's total assets as of December 31, 2024, were RMB 3,073,514,644.17, with total liabilities of RMB 2,080,120,300.01 and net assets of RMB 993,394,344.16 [13] - The company reported a revenue of RMB 1,597,172,881.12 and a net profit of RMB 52,163,151.56 for the same period [13] Group 6: Strategic Implications - The changes in fund usage are aligned with the company's long-term strategic planning and are expected to improve operational efficiency and competitiveness [19][20] - The company aims to leverage market trends and enhance its capabilities in innovative drug development, particularly in the chemical macromolecule sector [15][16]

Summary of Key Points Core Viewpoint - The company, Beijing Aerospace Changfeng Co., Ltd., is changing the use of raised funds from its 2022 private placement, terminating the "Energy Storage Power Verification Capability Construction Project" and permanently supplementing remaining funds into working capital due to changes in market conditions and strategic focus [2][4][6]. Group 1: Fundraising Overview - The company raised a total of RMB 325.26 million by issuing 27,752,474 shares at a price of RMB 11.72 per share [2]. - The funds were intended for projects including the enhancement of high-power density module power supply production and AI-based detection equipment development, with a total investment of RMB 393.04 million [2][3]. Group 2: Change of Fund Usage - The "Energy Storage Power Verification Capability Construction Project" was planned to invest RMB 63.52 million, with RMB 52.50 million from the raised funds, but has not yet utilized the funds [3]. - The decision to terminate this project is based on significant changes in the market environment and competitive landscape, which have compressed profit margins in the large energy storage industry [3][4]. Group 3: Remaining Fund Allocation - After terminating the project, the company plans to permanently allocate the remaining funds of RMB 53.88 million (including interest) to working capital, enhancing operational efficiency and strategic development [4][5]. - The company will close the corresponding special fund account and terminate the related fund supervision agreement after the transfer [4]. Group 4: Approval Process - The board of directors approved the change in fund usage unanimously on July 1, 2025, and the matter will be submitted to the shareholders' meeting for further approval [5][6]. - Independent directors and the supervisory board have expressed support for the decision, emphasizing that it aligns with the company's operational needs and does not harm shareholder interests [5][6].

Core Viewpoint - The company has decided to change the use of raised funds and permanently supplement the remaining funds into working capital, which is deemed a prudent decision based on market conditions and the company's strategic development needs [1][2]. Group 1 - The 15th meeting of the 10th Supervisory Board was held on July 1, 2025, with all three supervisors present, complying with relevant laws and regulations [1]. - The Supervisory Board unanimously approved the proposal to change the use of raised funds and permanently supplement the remaining funds into working capital, with a voting result of 3 votes in favor, 0 abstentions, and 0 votes against [2][3]. - The decision is based on a careful assessment of market environment changes, project implementation status, and the company's transformation and strategic development needs, aiming to improve the efficiency of fund usage without harming the interests of the company and its shareholders [2]. Group 2 - The proposal will be submitted to the company's shareholders' meeting for further approval [2].

Group 1 - The company has approved the investment in the Suez Phosphate Chemical Project in Egypt, which will produce 800,000 tons of sulfuric acid, 300,000 tons of industrial wet-process crude phosphoric acid, and 150,000 tons of other products annually [1] - The company plans to change the use of raised funds from a lithium iron phosphate precursor material project to the Suez Phosphate Chemical Project, pending approval from the upcoming shareholders' meeting [2] - The company has received necessary approvals from the Yunnan Provincial Development and Reform Commission and the Yunnan Provincial Department of Commerce for the overseas investment project [2]

Group 1 - The company announced a change in the use of part of the raised funds and a delay in investment projects, specifically reducing the investment amount for the "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" from 101.05 million yuan to 91.36 million yuan, reallocating 26 million yuan for the construction of the Hydrophilic Colloid Industrial Park Renovation and Digital Transformation Project (Phase I) [2] - The "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" was initially planned in 2022 based on market conditions and company circumstances, and the company has adhered to regulations regarding the use of raised funds while ensuring the project's smooth implementation [2] - As of May 31, 2025, the basic construction of the project, including civil works and equipment, has been completed [2] Group 2 - The company plans to extend the "Konjac Deep Processing Intelligent Manufacturing Production Line Expansion and Renovation Project" deadline to December 2025, utilizing working capital during the extension period to purchase raw materials needed for production [3] - The total planned investment for the "Hydrophilic Colloid Industrial Park Renovation and Digital Transformation Project (Phase I)" is 56.04 million yuan, with 26 million yuan sourced from the original raised funds, while the remaining amount will be financed through the company's own or self-raised funds [3] - The completion of the project is expected to enhance the company's production capacity for hydrophilic colloids, meet market demand, and improve the company's market competitiveness and profitability, thereby expanding future development opportunities [3]

Group 1 - The company, O-Film, announced on June 27 that it will hold the eighth (temporary) meeting of the sixth board of directors on June 27, 2025, to review the proposal for changing part of the fundraising purpose and adding new investment projects [2] - The company agreed to change the use of part of the raised funds, reallocating 200 million yuan from the "Hefei Jingchao Optical Technology Co., Ltd. Optical Lens and Lens Production Line Project" and 353.7568 million yuan from the "High-Pixel Optical Lens Construction Project" to the new project "High-Precision Optical Lens Production Line Upgrade and Expansion Project" [2] - The total amount of funds involved in this change is 553.7568 million yuan, which accounts for 15.76% of the net amount raised from the company's non-public stock issuance [2] Group 2 - The company’s revenue composition for the year 2024 is entirely from the manufacturing of optical and optoelectronic components, accounting for 100.0% [3]